Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical stage biotechnology company in immuno-oncology, and the news flow around SNSE reflects its focus on cancer drug development, clinical data, and corporate strategy. The company regularly issues press releases on quarterly financial results, clinical trial milestones, capital markets actions, and strategic decisions, which are then furnished to the SEC on Form 8-K.
Recent news has centered on solnerstotug, Sensei’s lead product candidate. The company has released updates from a multi-center Phase 1/2 trial evaluating solnerstotug, a conditionally active antibody targeting the VISTA checkpoint, as monotherapy and in combination with Libtayo® (cemiplimab) in patients with advanced solid tumors. These announcements have highlighted emerging clinical signals in PD-(L)1 resistant “hot” tumors, durability of progression-free survival, safety and tolerability data, and presentations at major scientific meetings such as the ESMO Congress.
Investors following SNSE news also see corporate and financial updates, including quarterly earnings releases, commentary on research and development and general and administrative expenses, and disclosures about cash, cash equivalents, and marketable securities. Sensei has additionally reported participation in investor and scientific conferences, such as healthcare and oncology events where company representatives discuss its tumor microenvironment–focused approach.
A key development in the company’s news stream is the strategic review announced on October 30, 2025, when Sensei’s Board decided to discontinue development of solnerstotug and explore strategic alternatives that may include asset sales, licensing, collaborations, a sale of the company, a business combination, a merger, or an orderly wind-down of operations. Subsequent news has described workforce reductions and the company’s intention to retain a smaller team to manage this process and maintain regulatory and financial reporting compliance.
This news page allows readers to track these evolving themes: clinical data releases, financial results, Nasdaq listing and reverse stock split actions, and updates on the strategic alternatives process, all of which shape the ongoing story of SNSE.
Sensei Biotherapeutics, a clinical-stage immunotherapy company, announced that CEO John Celebi will present at the Oppenheimer 31st Annual Virtual Healthcare Conference on March 16, 2021, at 9:20 a.m. ET. A live webcast of the presentation will be available on the company's website, with an archived version accessible for 90 days post-presentation.
Sensei Biotherapeutics focuses on developing next-generation immunotherapies, including its advanced therapy SNS-301, targeting tumor-associated antigens.
Sensei Biotherapeutics announced the closing of its initial public offering of 7,000,052 shares on February 8, 2021, with an additional 1,030,243 shares issued via an underwriter option on February 10, 2021. Priced at $19.00 per share, the gross proceeds totaled approximately $152.6 million, all from shares offered by Sensei. The company's stock trades on the Nasdaq Global Market under the ticker SNSE. Citigroup, Piper Sandler & Co., and Berenberg led the underwriting.
Cambrian Biopharma has successfully raised $60 million in private financing aimed at developing therapeutics to combat aging-related diseases. This funding coincides with the IPO of its portfolio company, Sensei Biotherapeutics (NASDAQ: SNSE), which began trading on February 4 and raised approximately $133 million in gross proceeds. Cambrian operates under a unique hub-and-spoke model to foster multiple drug discovery initiatives, targeting the 'Nine Hallmarks of Aging' through innovative therapies in fields like immunology and genomics.
Sensei Biotherapeutics has announced an upsized initial public offering (IPO) of 7,000,052 shares at $19.00 each, aiming to raise approximately $133 million. The shares will trade on Nasdaq under the ticker symbol SNSE starting February 4, 2021. Underwriters have an option to purchase an additional 1,050,007 shares. The offering is anticipated to close on February 8, 2021, pending market conditions. Sensei is known for its proprietary ImmunoPhage™ platform, which targets cancer and infectious diseases through innovative immunotherapy.